Ocuphire Pharma Investor Updates

P Percent of Subjects (%) Secondary Endpoint: % of Subjects ≥ 15 Letter Gain DCNVA (Monocular) Similar Results Were Seen Monocularly For Study Eye And Fellow Eye On Primary Endpoint Study Eye Percent of Subjects with ≥15 Letters DCNVA Improvement from Baseline 100% 90% 80% 70% 60% 50% 40% p=0.1 28% 30% 20% 10% 0% 14% 0 p=0.08 44% 26% 0.5 p=0.0008 p=0.002 54% 56% 16% 1 21% Placebo (n=43) 2 p=0.3 p=0.01 42% 40% 28% Time (Hours) 3 Nyxol+LDP (n=43) 16% VEGA-1 Phase 2 Trial 4 p=0.2 33% 19% 6 Percent of Subjects (%) 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Fellow Eye Percent of Subjects with ≥15 Letters DCNVA Improvement from Baseline p=0.3 21% 12% 0 p=0.001 p=0.001 49% 49% 14% 0.5 14% 1 Placebo (n=43) 17 Source: VEGA-1 TLR Table 14.2.1.2 Percent of Subjects With Improvement From Baseline in Photopic DCNVA by Time Point (PP Population) p=0.0003 49% p=0.02 p=0.02 40% 40% 9% 2 16% Time (Hours) 3 Nyxol+LDP (n=43) 16% 4 p=0.09 21% 7% 6 Ocuphire PHARMA

View entire presentation